Fredrik Frejd
Chief Scientific Officer Affibody AB
Seminars
Wednesday 24th February 2027
Matching Target, Molecule & Radionuclide to Improve Biodistribution
2:30 pm
- Understand how target biology and molecular format should inform early radiopharmaceutical design decisions
- Optimize Affibody-based targeting agents, chelators and radionuclide selection to improve biodistribution and tumor targeting
- Apply successes and failures from candidate development to identify which design characteristics are most likely to translate
